Expert Interview
Discussing the standard of care and the potential of 4D-150, a novel genetic medicine that utilizes 4DMT’s evolved and customized R100 vector for intravitreal delivery to the retina to treat wet AMD.
Ticker(s): FDMTInstitution: University of Pennsylvania
- Professor of Ophthalmology & Attending at the Hospital of the UPENN and the Presbyterian Medical Center of Philadelphia.
- Retina specialist who treats diabetics and uses Eylea on diabetics about 100 times a month.
- Has done research in diabetic retinopathy, has helped to develop techniques to measure the circulation in the eye, and is the Principal Investigator of two grants that will quantitate changes occurring in the retina due to diabetic retinopathy, systemic hypertension and age-related macular
degeneration
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
